Seeking Alpha
31 Oct 2026, 08:10 UTC · 2h ago
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach
Impact · against what's priced in
The earnings report and analyst rating provide no new catalyst for Novartis, as the near-term product pressures and long-term pipeline potential are already reflected in the current valuation. The stock remains a hold with a projected 12% downside based on these balanced headwinds and tailwinds.
- NVS−0.30
No priced-in read yet
- In context
The analyst maintains a 'Hold' rating with a price target of $141.81, suggesting a 12% downside driven by near-term product pressure offset by long-term pipeline potential.
Read from the article alone
Top 1 mover · tap to explore
